Oncorus, Inc.

OTCPK:ONCR Stock Report

Market Cap: US$3.3m

Oncorus Valuation

Is ONCR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ONCR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ONCR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ONCR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ONCR?

Key metric: As ONCR is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ONCR. This is calculated by dividing ONCR's market cap by their current book value.
What is ONCR's PB Ratio?
PB Ratio0.1x
BookUS$31.12m
Market CapUS$3.29m

Price to Book Ratio vs Peers

How does ONCR's PB Ratio compare to its peers?

The above table shows the PB ratio for ONCR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.6x
THAR Tharimmune
1.3xn/aUS$3.9m
BPTH Bio-Path Holdings
n/a54.2%US$3.4m
ONCT Oncternal Therapeutics
0.4x-29.5%US$3.4m
MTNB Matinas BioPharma Holdings
0.2x71.9%US$2.9m
ONCR Oncorus
0.1xn/aUS$3.3m

Price-To-Book vs Peers: ONCR is good value based on its Price-To-Book Ratio (0.1x) compared to the peer average (0.9x).

Price to Book Ratio vs Industry

How does ONCR's PB Ratio compare vs other companies in the US Biotechs Industry?

60 CompaniesPrice / BookEstimated GrowthMarket Cap
Industry Avg.1.9x28.4%
ONCR Oncorus
 0.1xn/aUS$3.29m
GRAL GRAIL
0.2x35.7%US$550.38m
IMAB I-Mab
0.4x1.8%US$78.16m
ONCR 0.1xIndustry Avg. 1.9xNo. of Companies82PB01.63.24.86.48+
60 CompaniesEstimated GrowthMarket Cap
Industry Avg.1.9x28.4%
ONCR Oncorus
 0.1xn/aUS$3.29m
No more companies

Price-To-Book vs Industry: ONCR is good value based on its Price-To-Book Ratio (0.1x) compared to the US Biotechs industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is ONCR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ONCR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ONCR's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Kiniksa Pharmaceuticals International

US$1.5b

A biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.

KNSA

US$21.28

7D

-0.05%

1Y

33.2%

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$17.12

7D

4.2%

1Y

79.3%